PSTV · Plus Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03M | - | $1.46M | $1.28M | $1.68M | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.87M | - | $2.44M | $1.25M | $1.76M | - | $2.86M | $2.77M | $2.76M | - |
| SG&A | $5.28M | - | $3.44M | $1.68M | $2.84M | - | $2.40M | $2.20M | $2.21M | - |
| Total Operating Expenses | $8.15M | - | $5.88M | $2.93M | $4.59M | - | $5.25M | $4.98M | $4.98M | - |
| D&A | $96.0K | - | - | - | $146.0K | - | - | - | $155.0K | - |
| Operating Income | ($7.12M) | - | ($4.48M) | ($1.54M) | ($3.54M) | - | ($3.80M) | ($3.70M) | ($3.30M) | - |
| Interest Expense | $17.0K | - | - | $27.0K | $34.0K | - | $87.0K | $27.0K | $34.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.95M) | - | ($4.42M) | $5.15M | ($17.40M) | - | ($2.87M) | ($2.94M) | ($3.26M) | - |
| EPS - Basic | ($1.05) | - | ($1.00) | $0.50 | ($29.75) | - | ($9.25) | ($11.25) | ($18.75) | - |
| EPS - Diluted | ($1.05) | - | ($1.00) | ($0.25) | ($29.75) | - | ($9.25) | ($17.75) | ($18.75) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.02M | $4.26M | $13.29M | $2.23M | $9.87M | $76.0K | $1.22M | $4.91M | $2.90M | $8.55M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | $3.28M | - | - | - | $9.47M | - | - | - | $4.76M |
| Current Assets | $18.03M | $15.17M | $17.59M | $9.21M | $10.87M | $5.26M | $5.36M | $9.38M | $4.21M | $9.83M |
| Total Assets | $19.92M | $16.32M | $18.67M | $10.35M | $12.06M | $6.63M | $6.98M | $11.21M | $5.62M | $11.39M |
| Current Liabilities | $7.96M | $12.31M | $13.62M | $7.32M | $10.56M | $15.55M | $12.11M | $18.79M | $10.40M | $10.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $7.96M | $12.33M | $13.62M | $7.32M | $35.70M | $15.58M | $12.15M | $18.84M | $10.46M | $12.74M |
| Stockholders' Equity | $11.96M | $4.00M | $5.05M | $3.03M | ($23.64M) | ($8.95M) | ($5.17M) | ($7.63M) | ($4.84M) | ($1.35M) |
| Retained Earnings | ($522.81M) | ($515.87M) | ($510.15M) | ($505.73M) | ($510.88M) | ($493.48M) | ($489.58M) | ($486.70M) | ($483.76M) | ($480.50M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.24M) | - | - | - | ($6.17M) | - | - | - | ($4.51M) | - |
| Investing Cash Flow | ($8.53M) | - | - | - | $3.56M | - | - | - | ($364.0K) | - |
| Financing Cash Flow | $9.04M | - | - | - | $12.40M | - | - | - | ($776.0K) | - |
| CapEx | $818.0K | - | - | - | $3.0K | - | - | - | $40.0K | - |
| Free Cash Flow | ($7.06M) | - | - | - | ($6.17M) | - | - | - | ($4.55M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -692.5% | - | -307.8% | -120.3% | -210.9% | - | - | - | - | - |
| EBITDA margin | -683.2% | - | - | - | -202.1% | - | - | - | - | - |
| Net margin | -675.7% | - | -303.8% | 402.7% | -1037.6% | - | - | - | - | - |
| Free cash flow margin | -686.4% | - | - | - | -368.2% | - | - | - | - | - |
| FCF / Net income | 1.02 | - | - | - | 0.35 | - | - | - | 1.40 | - |
| R&D / Revenue | 278.7% | - | 167.3% | 97.4% | 104.7% | - | - | - | - | - |
| SG&A / Revenue | 513.8% | - | 236.5% | 131.5% | 169.3% | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -34.9% | - | -23.7% | 49.8% | -144.3% | - | -41.2% | -26.2% | -58.0% | - |
| Return on equity | -58.1% | - | -87.5% | 169.8% | 73.6% | - | 55.5% | 38.6% | 67.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.27 | 1.23 | 1.29 | 1.26 | 1.03 | 0.34 | 0.44 | 0.50 | 0.41 | 0.92 |
| Quick ratio | 2.27 | 1.23 | 1.29 | 1.26 | 1.03 | 0.34 | 0.44 | 0.50 | 0.41 | 0.92 |
| Cash ratio | 0.38 | 0.35 | 0.98 | 0.31 | 0.93 | 0.00 | 0.10 | 0.26 | 0.28 | 0.80 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -418.8x | - | - | -57.0x | -104.0x | - | -43.7x | -136.9x | -97.0x | - |
| Equity multiplier | 1.67 | 4.09 | 3.69 | 3.41 | -0.51 | -0.74 | -1.35 | -1.47 | -1.16 | -8.45 |
| Liabilities / Assets | 0.40 | 0.76 | 0.73 | 0.71 | 2.96 | 2.35 | 1.74 | 1.68 | 1.86 | 1.12 |
| Efficiency | ||||||||||
| Asset turnover | 0.05 | - | 0.08 | 0.12 | 0.14 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.2x | - | 361.4x | 603.2x | - | - | - | - | - | - |
| P / S | 25.9x | - | 1254.3x | 1430.9x | 206.3x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -38.7% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -101.3% | - | -18.0% | 58.4% | -7.2% | - | -16.9% | -148.1% | 30.1% | - |
| Net income growth (YoY) | 60.1% | - | -53.9% | - | -433.6% | - | 10.7% | -98.4% | 32.1% | - |
| EPS growth (YoY) | 96.5% | - | 89.2% | 98.6% | -58.7% | - | -825.0% | -2908.5% | -13292.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -14.3% | - | - | - | -35.6% | - | - | - | 22.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -388.8% | -563.9% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$5.20M totalGrant$5.20M · 100.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing PLUS THERAPEUTICS against the 5 most active filers in the same SIC group.